1. European Monitoring Centre for Drugs and Drug Addiction.Report on the risk assessment of methyl 2‐{[1‐(5‐fluoropentyl)‐1H‐indazole‐3‐carbonyl]amino}‐3 3‐dimethylbutanoate (5F‐MDMB‐PINACA; 5F‐ADB) in the framework of the Council Decision on new psychoactive substances. Risk Assessments Publications Office of the European Union Luxembourg 2018.http://www.emcdda.europa.eu/publications/risk-assessments/5f-mdmb-pinaca_en(accessed May 16 2019).
2. European Monitoring Centre for Drugs and Drug Addiction.EMCDDA‐Europol joint report on a new psychoactive substance: methyl 2‐{[1‐(5‐fluoropentyl)‐1H‐indazole‐3‐carbonyl]amino}‐3 3‐dimethylbutanoate (5F‐MDMB‐PINACA; 5F‐ADB). Publications Office of the European Union Luxembourg 2017.http://www.emcdda.europa.eu/publications/joint-reports/5F-MDMB-PINACA_en(accessed May 16 2019).
3. European Monitoring Centre for Drugs and Drug Addiction.Synthetic cannabinoids in Europe perspectives on drugs publications. Office of the European Union Luxembourg 2017.http://www.emcdda.europa.eu/publications/pods/synthetic-cannabinoids_en(accessed May 16 2019).
4. Pharmacology of Valinate and tert-Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their Analogues
5. Identification and quantitation of 5-fluoro-ADB, one of the most dangerous synthetic cannabinoids, in the stomach contents and solid tissues of a human cadaver and in some herbal products